O’Melveny Represents TransThera Sciences in New H-Share Placement
January 20, 2026
FOR IMMEDIATE RELEASE
HONG KONG—January 20, 2026—O’Melveny represented TransThera Sciences (Nanjing), Inc. (“TransThera”, 2617.HK) in its placing of 2,100,000 new H shares under general mandate, at HK$92.85 per placing share. The net proceeds is approximately HK$190 million (approximately US$24 million). CLSA Limited acted as the sole placing agent and sole overall coordinator.
The placement was announced on January 14, 2026 and completed on January 20, 2025. Proceeds will support the ongoing trial of TransThera’s core product Tinengotinib, further research and development of other products, and general corporate purposes.
O’Melveny also represented TransThera in its Hong Kong IPO in 2025. TransThera is a clinical demand-oriented biopharmaceutical company focusing on developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases.
The O’Melveny team was led by partners Ke Geng and Ke Zhu. The core team members included counsel Edward Poon and trainee solicitor Priscilla Yeung. Associate Jingwei Huang and legal consultant Lily Ling also contributed.
About O’Melveny
It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at www.omm.com; learn more in our firm at-a-glance; and find us on LinkedIn, Facebook, Instagram, and YouTube.
Contact:
Brandon Jacobsen
O’Melveny & Myers LLP
+1 213 430 8024
bjacobsen@omm.com
Chris Schob
O’Melveny & Myers LLP
+86 21 2307 7000
cschob@omm.com
# # #